Biopsy for advanced hepatocellular carcinoma: results of a multicentre UK audit.

ABSTRACT:

Background

Advanced hepatocellular carcinoma (HCC) is commonly diagnosed using non-invasive radiological criteria (NIRC) defined by the European Association for the Study of the Liver or the American Association for the Study of Liver Diseases. In 2017, The National Institute for Clinical Excellence mandated histological confirmation of disease to authorise the use of sorafenib in the UK.

Methods

This was a prospective multicentre audit in which patients suitable for sorafenib were identified at multidisciplinary meetings. The primary analysis cohort (PAC) was defined by the presence of Child-Pugh class A liver disease and performance status 0-2. Clinical, radiological and histological data were reported locally and collected on a standardised case report form.

Results

SUBMITTER: Childs A 

PROVIDER: S-EPMC8575957 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature